Diagnostic efficacy of liquid-based cytology, liquid-based cytology with HPV triage, HPV, and HPV with liquid-based cytology triage, using CIN2+ and CIN3+ as reference (n=4043)
| Diagnostic test at baseline % (95% CI) | ||||
| Liquid-based cytology | Liquid-based cytology +HPV triage | HPV | HPV+ liquid-based cytology triage | |
| Reference: CIN2+ | ||||
| Sensitivity | 46.9% (30/64) (34.3% to 59.8%) | 42.2% (27/64) (29.9% to 55.2%) | 82.8% (53/64) (71.3% to 91.1%) | 54.7% (35/64) (41.7% to 67.2%) |
| Specificity | 96.9% (3,855/3,979) (96.3% to 97.4%) | 98.7% (3,927/3,979) (98.3% to 99.0%) | 93.2% (3,708/3,979) (92.4% to 94.0%) | 97.9% (3,894/3,979) (97.4% to 98.3%) |
| Positive predictive value | 19.5% (30/154) (13.5% to 26.6%) | 34.2 (27/79) (23.9% to 45.7%) | 16.4% (53/324) (12.5% to 20.8%) | 29.2% (35/120) (21.2% to 38.2%) |
| Negative predictive value | 99.1 (3,855/3,889) (98.8% to 99.4%) | 99.1% (3,927/3,964) (98.7% to 99.3%) | 99.7% (3,708/3,719) (99.5% to 99.9%) | 99.3% (3,894/3,923) (98.9% to 99.5%) |
| Reference: CIN3+ | ||||
| Sensitivity | 47.5% (19/40) (31.5% to 63.9%) | 45.0% (18/40) (29.3% to 61.5%) | 90.0% (36/40) (76.3% to 97.2%) | 67.5% (27/40) (50.9% to 81.4%) |
| Specificity | 96.6% (3,868/4,003) (96.0% to 97.2%) | 98.5% (3,942/4,003) (98.0% to 98.8%) | 92.8% (3,715/4,003) (92.0% to 93.6%) | 97.7% (3,910/4,003) (97.2% to 98.1%) |
| Positive predictive value | 12.3% (19/154) (7.6% to 18.6%) | 22.8% (18/79) (14.1% to 33.6%) | 11.1% (36/324) (7.9% to 15.0%) | 22.5% (27/120) (15.4% to 31.0%) |
| Negative predictive value | 99.5% (3,868/3,889) (99.2% to 99.7%) | 99.4% (3,942/3,964) (99.2% to 99.7%) | 99.9% (3,715/3,719) (99.7% to 100.0%) | 99.7% (3,910/3,923) (99.4% to 99.8%) |